Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerNICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in Share XUnconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerhttps://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/
Angelini and Arvelle create neurology player with $960m mergerThere’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Share XAngelini and Arvelle create neurology player with $960m mergerhttps://pharmaphorum.com/news/angelini-and-arvelle-create-neurology-player-with-960m-merger/
EMA will use Panalgo software for real-world data analyticsSix months after rebranding from BHE, Panalgo has won a contract to supply the European Medicines Agency (EMA) Share XEMA will use Panalgo software for real-world data analyticshttps://pharmaphorum.com/news/ema-will-use-panalgo-software-for-real-world-data-analytics/
Pfizer/BioNTech shot may beat new virus mutation, study findsThe Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in Share XPfizer/BioNTech shot may beat new virus mutation, study findshttps://pharmaphorum.com/news/pfizer-biontech-vaccine-may-work-against-new-virus-mutation-scientists-say/
IL-6 drugs do work in COVID-19, says UK, as it plans NHS useNew data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus Share XIL-6 drugs do work in COVID-19, says UK, as it plans NHS usehttps://pharmaphorum.com/news/il-6-drugs-covid-19-new-trial/
UK left trailing as EU quickly approves Moderna’s COVID-19 vaccineThe European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to Share XUK left trailing as EU quickly approves Moderna’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-left-trailing-as-eu-quickly-approves-modernas-covid-19-vaccine/
Bayer joins the COVID-19 vaccine push, backing CureVac shotShortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to Share XBayer joins the COVID-19 vaccine push, backing CureVac shothttps://pharmaphorum.com/news/bayer-joins-the-covid-19-vaccine-push-backing-curevacs-shot/
AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
